Furthermore, GLP-1-based medications such as GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors, have been shown to improve diabetes control in preclinical and clinical trials with human subjects
Some patch ingredients (berberine, green tea catechins) have shown modest GLP-1 signaling effects in animal models with oral dosing at gram-level quantities
A year later Thorens published a second paper together with collaborators in Lausanne reporting on the cloning, sequencing and functional expression of the human GLP-1 receptor (Thorens, Porret, Bhler)
In the second trial, SURPASS-2, tirzepatide administered at doses of 5 mg, 10 mg, or 15 mg showed superior efficacy compared to semaglutide (1 mg) in reducing body weight and HbA1c levels over 40 weeks in patients with T2DM inadequately controlled with metformin [66]